| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
V40313-1mg |
≥99% | ￥3590.00 |
货期：3-5天 | - | - | - | - |
|
V40313-5mg |
≥99% | ￥5770.00 |
货期：3-5天 | - | - | - | - |
|
V40313-10mg |
≥99% | ￥9180.00 |
货期：3-5天 | - | - | - | - |
|
V40313-25mg |
≥99% | ￥13600.00 |
货期：3-5天 | - | - | - | - |
|
V40313-50mg |
≥99% | ￥17800.00 |
货期：3-5天 | - | - | - | - |
|
V40313-100mg |
≥99% | ￥24900.00 |
货期：3-5天 | - | - | - | - |
|
| 靶点： | PAF | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 体内研究： | 48740 RP ((Rac)-RP-55778) is a platelet-activating factor (PAF) antagonist. In animals treated with 48740 RP only, the number of platelets is increased at a time corresponding to 2 and 4 h after the exposure to lipopolysaccharide (LPS) and the number of eosinophils is also slightly increased. Treatment with 48740 RP in combination with the LPS exposure does not influence the increase in neutrophils seen 2 and 4 h after exposure. At 24 h the increase in the number of neutrophils is about half that in control animals. No effects are found on the LPS-induced increase in number of platelets. In animals pretreated with 48740 RP, there is a significant reduction in capillary permeability. | ||||||||||||||||||||
| 参考文献： | 1. Rylander R, et al. Modulation of pulmonary inflammation after endotoxin inhalation with a platelet-activating factor antagonist (48740 RP). Int Arch Allergy Appl Immunol. 1988;86(3):303-7. | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京